Startups
Shasqi is leading the development of therapeutics leveraging click chemistry to get active cancer treatments to tumors with its proprietary CAPAC™ (Click Activated Protodrugs Against Cancer) platform. The technology is based on localizing a click chemistry reagent in the tumor area, which then activates a second agent, a systemically infused protodrug. When the two ‘click’, a powerful localized therapy is activated at the tumor, while keeping its systemic exposure levels below toxic thresholds. We have already proven that our platform works in humans, which opens up an array of future possibilities for click-chemistry based therapies.
Overview
Location
United States, California, San Francisco
Employees
11-50
Total raised
$1.9M
Founded date
2015
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 7
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Nov 11, 2021 | What does the recent third quarter drop in late-stage startup valuations mean? | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. With decacorns born left and right nowadays, it’s hard to believe that valuations are pulling bac... |
| Nov 11, 2021 | Shasqi Raises $50 Million to Expand Click Chemistry Platform Beyond Injectable Tumors and Accelerate Lead Clinical Program | Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC™) Platform, announced today a Series B funding round of $50 million dr... |
| Oct 14, 2020 | First YC Bio company to start clinical trials | Shasqi is the first YC Bio company to start first-in-human clinical trials for a drug. We’re very excited to share the news that Shasqi is the first YC Bio company to have a drug enter first-in-human clinical trials1. Shasqi is developing ... |
| Aug 5, 2019 | How Biotech Startup Funding Will Change in the Next 10 Years | Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade – accurately, it turns out. Paul Graham predicted that there would be way more sta... |
| How Biotech Startup Funding Will Change in the Next 10 Years | Back when YC was getting started about 10 years ago, Paul Graham wrote some essays that predicted the way startup fundraising would change in the next decade - accurately, it turns out. Paul Graham predicted that there would be way more sta... | |
| It takes two: The future of click chemistry therapeutics | A major challenge in the development of novel therapeutics is the precise localization and activation of drugs to specific areas in the body. Twenty years ago ‘click chemistry’, a simple yet powerful concept to tackle this challenge, was fi... |
Reviews 0
FAQ about Shasqi
When was Shasqi founded?
Shasqi was founded in 2015.
How much funding has Shasqi raised?
Shasqi has raised $1.9M in total across 1 funding round.
What has the press written about Shasqi?
Parsers VC has collected 7 articles mentioning Shasqi, among them “What does the recent third quarter drop in late-stage startup valuations mean?” (Nov 11, 2021) and “Shasqi Raises $50 Million to Expand Click Chemistry Platform Beyond Injectable Tumors and Accelerate Lead Clinical Program” (Nov 11, 2021).
Is Shasqi still active?
Yes, Shasqi is active; its latest activity on Parsers VC dates from Nov 11, 2021.